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Nowadays, we face growing resistance among gram-positive and gram-negative pathogens that cause
respiratory infection in the hospital and in the community. The spread of penicillin- and macrolide-
resistant pneumococci, Communityeacquired methicillin-resistant staphylococcus aureus (Ca-MRSA),
the emergence of glycopeptide-resistant staphylococci underline the need for underline the need for
therapeutic alternatives. A number of new therapeutic agents, with activity against the above Gram (þ)
respiratory pathogens, as ceftaroline, ceftopibrole, telavancin, tedizolid have become available, either in
clinical trials or have been approved for clinical use. Especially, the development of new oral antibiotics,
as nemonaxacin, omadacyclin, cethromycin and solithromycin will give a solution to the lack of oral
drugs for outpatient treatment. In the future the clinician needs to optimize the use of old and new
antibiotics to treat gram (þ) respiratory serious infections.
© 2014 Elsevier Ltd. All rights reserved.96
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Lower respiratory tract infections (LRTIs) as acute exacerbations
of chronic bronchitis, community-acquired pneumonia (CAP) and
hospital acquired pneumonia (HAP) are one of the most common
diseases in humans and a long-term global public health concern.
Within Europe, CAP is the leading cause of death due to infec-
tion [1] with approximately 90% of deaths due to pneumonia
occurring in people aged >65 years. Ventilator-associated pneu-
monia (VAP),representing 80% of HAP, is reported to be the most
common hospital-acquired infection among patients requiring
mechanical ventilation, carrying an attributable mortality of
33e60%.u).
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u A, et al., New antimicrob
/dx.doi.org/10.1016/j.pupt.201Streptococcus pneumoniae, Haemophilus influenzae, Moraxella
catarrhalis, Staphylococcus aureus, Enterobacteriacea, Pseudomonas
aeruginosa and Mycoplasma pneumoniae, Chlamydophila pneumo-
niae and Legionella pneumophila causing atypical pneumonias are
the major pathogens implicated in respiratory tract infections.
Nowadays, multi-drug-resistant bacteria have emerged
throughout the world with more than one third of the isolates are
multidrug-resistant (MDR) [2], and half the deaths from clinical
infection in Europe are associated with MDR bacteria [3]. The
increasing problem of antibiotic resistance means that community
and hospital LRTIs are becoming progressively more difficult to
diagnose and treat.
In a recent review Welte et al., analyzing forty-six primary ar-
ticles of CAP, S. pneumoniae was reported as the most frequently
pathogen, being isolated in 38% of outpatient cases, 27% of inpatient
cases, and 28% of CAP patients admitted in the ICU [4]. In the
AWARE Ceftaroline Surveillance Program (2008e2010) showed117
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contained up to 21.1% penicillin-resistant strains (using CLSI criteria
for penicillin [oral penicillin V]) [5].
Among the Gram-positive respiratory organisms, S. pneumoniae
resistant to penicillin and macrolides and methicillin-resistant S.
aureus (MRSA) represent the biggest therapeutic hurdles.
Rates of penicillin resistance of S. pneumoniae exceeding 50%
occur in certain areas of the world, such as Asia, 25% in some
Mediterranean countries but remain low (<5%) in other regions,
such as Finland and Sweden [6]. Worldwide, penicillin-resistant
strains of pneumococci are usually also resistant to tetracycline,
erythromycin and chloramphenicol. Reports from Germany, USA
and other European and Asian countries showed a resistance rate of
S pneumoniae to macrolides that varies from 18% to 75% [7-8].
S. aureus is the predominant Gram positive pathogen in HAP and
VAP. Data from the National Nosocomial Infections Surveillance
system of USA suggest that in ICUs the [9] proportion of MRSA has
increased to 59.5%e64.4%. MRSA is also commonly isolated in pa-
tients with HAP in European ICUs. Koulenti et al. [10] reported that
MRSA was isolated in 16% of patients with nosocomial pneumonia
(21.4% in HAP and 14.6% in VAP). Coma is the primary risk factor for
VAP caused by methacillin sensitive S. aureus (MSSA) and risk fac-
tors for VAP caused by MRSA include corticosteroid therapy, me-
chanical ventilation longer than 6 days, >25 yrs of age, prior
diagnosis of COPD, and previous use of antibiotics [11].
Another large, prospective study reporting 474 patients with
VAP in Spain found that patients with MRSA VAP had significantly
higher in-hospital mortality than patients with VAP caused by
other microorganisms (59.5% versus 46.8%; p 0.02) [12].
Evenmore, the appearance of glycopeptide non-susceptibility
among staphylococci, mainly of the vancomycin-intermediate
(VISA) and hetero-VISA (hVISA) varieties, makes these infections
more difficult to treat [13].
Therefore, new oral and/or parenteral antimicrobial agents with
activities against these Gram-positive respiratory pathogens are in
demand. To improve our fight against MRSA there are new oxa-
zolidinone (tedizolid) and the extended spectrum cephalosporins,
ceftobiprole and ceftaroline treating CAP and HAP. New agents
which target protein synthesis and a quinolone are in development
for the treatment of moderate to severe respiratory infections:
solithromycin, cethromycin and nemonoxacin.
This review is intended to raise awareness of several novel ap-
proaches to combating the emergence of Gram (þ) positive-
especially MDR-respiratory bacteria which are becoming more
commonplace in our hospitals and even in our community settings.
2. Approved antimicrobials
A number of new therapeutic agents against Gram (þ) respira-
tory pathogens have been approved for clinical use the last 3 years,
including: ceftaroline, ceftobiprole and telavancin (Table 1).Table 1
New antimicrobials against Gram (þ) respiratory infections.
Compound Formulation Clinical indication St
Telavancin Lipoglycopeptide cSSSIs in USA
HAP in Europe
Ap
Ceftaroline Cefalosporin cSSSIs and CAP Ap
Ceftobiprole Cefalosporin HAP, excluded VAP Ap
Omadacycline Tetracycline cSSSIs, CAP Ph
Cethromycin Ketolide CAP Ph
Solithromycin Ketolide CAP Ph
Tedizolid oxazolidinone cSSSIs and HAP Ph
Nemonoxacin Quinolone CAP Ph
NDA: new drug application, cSSSIs: complicated skin and skin structure infection, CAP:
Please cite this article in press as: Liapikou A, et al., New antimicrob
Pharmacology & Therapeutics (2014), http://dx.doi.org/10.1016/j.pupt.2013. Ceftaroline
Ceftaroline fosamil is a new, bactericidal, parental, extended
spectrum cephalosporin (Table 2) with activity against Gram pos-
itive organisms, including S. pneumoniae, Streptococcus pyogenes,
S. aureus (including MRSA and vancomycin-resistant S. aureus
(VRSA) and hetero-resistant VISA (hVISA), as well as many common
Gram-negative organisms, as Hemophilus influenzae and Moraxella
catarrhallis.
Like other b-lactam antibiotics, prevents cell wall formation
by binding to the penicillin-binding protein (PBP), especially
to PBP e 2a, which confers the methicillin resistance in
S. aureus. The MIC90 with a range of 0.25e1 against S. aureus
tends to be low [14] and an MIC of 1 mg/mL is considered
susceptible.
Ceftaroline is active against S. pneumoniae, including penicillin-
intermediate and-resistant strains [15]. Ceftaroline exhibits potent
in vitro activity against S. pneumoniae with MIC90 values for
penicillin-susceptible, penicillin intermediate and penicillin-
resistant strains of 0.015 mg/L, 0.06 mg/L and 0.12 mg/L, respec-
tively [14].
Using single-step and multistep passages, no resistant mutants
were selected with ceftaroline in staphylococci, pneumococci, or
H. influenzae [16].
Ceftaroline has limited protein binding (1e19%) and achieved
good lung penetration (40%) in a rabbit model [17]. The major
route of elimination is renal excretion with an average t½ is
2.6 h.
Phase III clinical trials have found that ceftaroline is non-inferior
to comparator therapy for the treatment of community acquired
pneumonia (FOCUS 1 and 2 trials; comparator: ceftriaxone), with
cure rates of ceftaroline >82% [18]. Evenmore, in a retrospective
integrated analysis of the FOCUS trials clinical response rates
associated with the most common pathogens were numerically
higher for ceftaroline compared to ceftriaxone (84% vs. 78%,
respectively) [19].
Ceftaroline is usually well tolerated, and in clinical trials only
about 3% of subjects discontinued therapy due to adverse effects,
most commonly due to allergic reactions. The most common
adverse effects were rash, diarrhea, diarrhea, headache, hypo-
kalaemia, insomnia and phlebitis [18].
It has been the only FDA (10/2010) approved cephalosporin for
treatment of skin and soft tissue infections (cSSSIs) and CAP, in an
i.v. dosis of 600 mg/12 h.
The positive attributes of ceftaroline with respect to antimi-
crobial stewardship programs are: the low potential for resistance
development and the favorable safety and tolerability profile in
clinical trials.
Its limitations are the dosing regimen: three times daily for
invasive infections (no data available for continuous infusion), and
the absence of an oral formulation.age of development Side effects
proved Taste disturbance, foamy urine, renal
impairment
proved by FDA and EMA Hypersensitivity reactions, Clostridium
difficile-associated Diarrhea,
proved in Europe Nausea, Vomiting, taste disturbance
ase III cSSTI completed Nausea, elevation of ALT levels
ase III Diarrhea, dysgeusia, headache
ase III Diarrhea, headache and nausea
ase III cSSTI & HAP Nausea, diarrhea, headache, vomiting
ase III clinical trial in CAP Headache, contact dermatitis, pruritus, rash
community acquired pneumonia.
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Table 2
Chemical structures of new antibiotics.
Antibiotics Chemical figures
1. Ceftaroline
2. Ceftopibrole
3. Telavancin
4. Cethromycin
5. Solithromycin
(continued on next page)
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Table 2 (continued )
Antibiotics Chemical figures
6. Nemonoxacin
7. Omadacycline
8.Tedizolid
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Ceftobiprole is a new member of the pyrrolidone-3-
ylidenemethyl cephem series of cephalosporins. It is active
against pneumococci, S. aureus-including MRSA and vancomycin-
intermediate S. aureus (VISA), Enterococcus faecalis and Gram-
negative bacilli-especially has anti-pseudomonal activity similar
to cefepime and some anaerobes [20].
Like ceftaroline has strong binding affinity to PBP-2x and PBP-2a
resulting in bactericidal activity against resistant S. pneumoniae and
Ca-MRSA.
MICs for all streptococcal species, except the penicillin-resistant
Streptococcus viridans, but including penicillin-resistant S. pneu-
moniae, ranged from <or ¼0.008e2.0 mg/L. Ceftobiprole is active
against E. faecalis but generally not active against Enterococcus
faecium. A surveillance study on S. pneumoniae called, TRUST 12,
showed that ceftobiprole was themost potent cephalosporin tested
against S. pneumoniaewithМІC50 (0.015 mg/mL) and MIC90 (0.5 mg/
mL) with values two-fold lower than ceftriaxone [21].
PK/PD studies in humans demonstrate that ceftobiprole has an
elimination half-life of about 3 h and predominantly urinary
excretion.
In the phase III study published by Nicholson et al. [22], cefto-
biprole 500 mg every 8 h was non-inferior to ceftriaxone with or
without linezolid for the treatment of CAP patients. Also, for HAP, a
phase III clinical trial demonstrates the noninferiority of ceftobi-
prole plus placebo compared with linezolid plus ceftazidime with
respect to the clinical cure (77% for ceftobiprole and 76% for com-
bination therapy). However, ceftobiprole was inferior in the sub-
group of patients undergoing mechanical ventilation (VAP) [13].
In a more recent review about ceftobiprole [23], reported that in
patients with normal PK and non-VAP, ceftobiprole is effective for
the treatment of HAP in the recommended doses, but it is unlikelyPlease cite this article in press as: Liapikou A, et al., New antimicrob
Pharmacology & Therapeutics (2014), http://dx.doi.org/10.1016/j.pupt.201to achieve the desired PD targets when PK parameters are altered in
VAP (e.g., increased Vd and Cl). Τhat’s why it has been approved in
Europe for HAP, but not VAP.
It is well tolerated with frequently reported adverse effects
included taste disturbances, nausea and vomiting.
5. Telavancin
Telavancin is a vancomycin-derived lipoglycopeptide which is
characterized by a broad spectrum of microbiologic activity against
Gram-positive bacteria, such as S. pneumoniae independent of
penicillin susceptibility and staphylococci (including MRSA, hVISA
and VISA strains) [24].
Its antibacterial effects are proposed to be achieved through a
dual mechanism of action, i.e. inhibition of cell wall peptidoglycan
synthesis and depolarization of the cell membrane, resulting in
disruption of the functional integrity [25].
The excellent activity of telavancin against Staphylococcus spp.
represents the main characteristic of this compound. MIC values
(MIC90) of tested strains between 0.25 and 1 mg/L have been re-
ported in an over 4500 isolates of MSSA and MRSAworldwide [26].
Against S. aureus with reduced susceptibility to glycopeptides,
telavancin retains some activity but with elevated MICs [27]. In
several studies, telavancin MICs for MRSA ranged from two to eight
times lower than those observed for vancomycin, teicoplanin and
linezolid.
It is highly protein bound estimated at 93% and has a long half-
life (up to 9 h), so that it can be given once a day. Telavancin
excreted mainly via the kidneys, so the dose of the drug needs
adjustment for patients with moderate renal insufficiency.
Telavancin distributed into lung tissue with epithelial lining
fluid concentrations of approximately two- to eightfold above the
MIC90 of S. aureus for 24 h. Post antibiotic effect of 4e6 h wereial approaches to gram positive respiratory infections, Pulmonary
4.05.003
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MSSA and MRSA [28].
Telavancin has been also evaluated in two studies (ATTAIN 1e2)
in the treatment of HAP due to Gram-positive cocci, particularly
MRSA. In these studies telavancin was noninferior to vancomycin
on the basis of clinical response in the treatment of HAP, especially
clinical cure: 82% telavancin. vs. 74% for vancomycin. But in patients
with pre-existing moderate/severe renal impairment
(CrCl < 50 mL/min) telavancin presented an increased mortality
compare to vancomycin [29].
Responding to this result. in a post hoc analysis of data from two
Phase 3 ATTAIN trials [30] excluding patients with severe renal
impairment (creatinine clearance <30 mL/min, including patients
on haemodialysis) and pre-existing acute renal failure, the clinical
and safety outcomes were similar in the telavancin and vancomycin
treatment groups.
The ATTAIN studies also reported adverse events being gastro-
intestinal discomfort and taste disturbance, nausea, headache,
vomiting, insomnia and foamy urine.
FDA and European Medicines Agency (EMEA) accepted tela-
vancin for the treatment for adults with nosocomial pneumonia,
including VAP known or suspected to be caused by MRSA, in pa-
tients without renal insufficiency [31].
6. Under development antimicrobials
6.1. Cethromycin
Cethromycin is a new fluoroketolide with a reported high po-
tency against Gram-positive, Gram-negative bacteria and atypicals
including mycoplasma and ureaplasma. It has also in vitro activity
against penicillin- and macrolide-resistant Gram-positive organ-
isms, possibly due to a higher affinity for the target site on the ri-
bosomal unit [32].
The SENTRY Antimicrobial Surveillance Program platform has
shown that cethromycinwas highly active in vitro against all Gram-
positive organisms (MIC50, 0.015 mg/mL) as compared with teli-
thromycin (MIC50, 0.06 mg/mL), clarithromycin (MIC50, 0.12 mg/mL),
and erythromycin (MIC50, 0.25 mg/mL) [33]. Cethromycin had
excellent activity against S. pneumoniae, including isolates
harboring mef (A) (MIC90, 0.06 mg/mL), or erm (B) (MIC90, 0.25 mg/
mL), penicillin-resistant pneumococci (MIC90, 0.12 mg/mL), and
serotype 19A pneumococci (MIC90, 0.12 mg/mL) [34].
Cethromycin distributes well into pulmonary compartments
and at concentrations higher than plasma, with a daily dose of 150
or 300mg yielding a Cmax in the ELF of 0.94 or 2.75 mg/mL in two to
four hours and AUC0e24values of 11.4 and 24.15 mg h/mL [35].
There are two comparative CAP studies of cethromycin 300 mg
per day to clarithromycin 250 mg twice a day that demonstrating
the noninferiority of cethromycin in terms of clinical cure and
radiographic improvement [36], in low severity CAP patients. The
reported most common adverse events were diarrhea, nausea,
dysgeusia and headache.
Cethromycin completed Phase III clinical trials for the treatment
of CAP and was deemed to be safe according to the FDA Advisory
Committee, after dosing more than 5000 patients in 53 clinical
studies for patients with mild or moderate CAP [37]. But more trials
will be needed with more severe CAP patients before approval can
be granted.
7. Solithromycin
Solithromycin is a novel fluoroketolide with high potency
against Gram-positive and Gram-negative bacteria commonly
associated with community-LRTIs. Against strains with definedPlease cite this article in press as: Liapikou A, et al., New antimicrob
Pharmacology & Therapeutics (2014), http://dx.doi.org/10.1016/j.pupt.201susceptibilities to erythromycin, clindamycin and telithromycin,
solithromycin showed potent inhibition against all combinations
(MIC50 ¼ 0.06 mg/mL) except those with non-susceptibility to teli-
thromycin (>2 mg/mL) (MIC50 > 16 mg/mL) [38].
Solithromycin has in vitro potency against the major CABP
pathogens, S. pneumoniae (MIC90, 0.03 g/mL), Haemophilus influ-
enzae (MIC90, 2 mg/mL), Moraxella catarrhalis (MIC90, 0.06 mg/mL),
and MSSA; MIC90, 0.06 mg/mL), including intracellular pathogens
Legionella pneumophila (MIC90, 0.016 mg/mL), Chlamydia pneumo-
niae (MIC90, 0.25 mg/mL), and Mycoplasma pneumoniae (MIC90,
0.000125 mg/mL).
The half-life increased with dose and averaged 5.1e6.5 h for the
400e800 mg dose. A phase 1 study to determine the ELF and
alveolar macrophage (AM) levels of solithromycin after five days of
oral dosing of 400 mg q24 h found the exposure (AUC0e24) of
solithromycin in ELF and AM was >8 times and 180 times higher
than the total plasma exposure, respectively [39].
A completed Phase 2 study showed comparable efficacy of sol-
ithromycin 800 mg on day 1 followed by 400 mg on days 2e5 to
levofloxacin 750 mg once daily in adults with PSI-II to PSI-IV CABP
[40]. A new global Phase 3 trial of solithromycin in patients with
CABP includes a double-blind, placebo-controlled, multicenter
study enrolling ~800 CAP patients and randomize them to either
oral solithromycin, an 800 mg loading dose followed by 400 mg
once daily for 5 days or once-daily oral moxifloxacin 400 mg for 7
days is taken place now and the results are expected with interest
[41].
Across all the studies, the most common adverse events of the
drug were diarrhea (13%), headache (13%) and nausea (10%), most
of which were mild.
8. Nemonoxacin
Nemonoxacin is a novel non-fluorinated quinolone that is a
broad-spectrum, once daily oral therapy for cSSSI and CAP.
Nemonoxacin displayed greater activity than the fluo-
roquinolones (levofloxacin) against MSSA, MSSE, MRSE,
S. pneumoniae, and E. faecalis. Interestingly, nemonoxacin main-
tained better activity against CA-MRSA than against HA-MRSA. It
has also demonstrated a potent antibacterial activity against
ciprofloxacin-resistant MRSA, methicillin- and levofloxacin-
resistant Staphylococcus capitis, penicillin and levofloxacin-
resistant S. pneumoniae and VRE [42,43].
Oral nemonoxacin (750 mg or 500 mg) administered once daily
for seven days showed similar clinical and bacteriological response
as levofloxacin (500 mg once daily) in the therapy of CAP [44].
Usual adverse events were diarrhea, dizziness and headache.
It has currently completed one FDA Phase 2 trial specifically for
diabetic foot infections and 2 new Phase 3 clinical comparative
trials with levofloxacin in patients with CAP [45].
9. Omadacycline
Omadacycline, an aminomethylcycline, is a semisynthetic de-
rivative of minocycline that has in vitro potency against Gram-
positive and Gram-negative bacteria and atypicals (L. pneumo-
phila) causing ASSSIs and CAP.
Like tigecycline, potent activity was observed in vitro against
resistant Gram-positive bacteria, with MIC90 values 0.5 mg/ml.
The omadacycline MIC90s for MRSA, VRE, and beta-hemolytic
streptococci were 1.0 mg/mL, 0. 25 mg/mL, and 0.5 mg/mL, respec-
tively, and for PRSP and H. influenzae were 0.25 mg/mL and 2.0 mg/
mL, respectively. Omadacycline was active against organisms
demonstrating the two major mechanisms of resistance, ribosomal
protection and active tetracycline efflux [46].ial approaches to gram positive respiratory infections, Pulmonary
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doxycycline, minocycline, clindamycin, linezolid, or vancomycin
against enterococcus, including vancomycin-resistant E. faecalis or
E. faecium, and S. pneumoniae strains including penicillin- and
multiresistant strains.
Omadacycline is metabolically stable and has demonstrated low
protein binding across all concentrations and species tested [47]
and is orally absorbed.
In a Phase 3 study of patients with complicated skin and soft
tissue infections (cSSSI), oral and i.v. omadacycline was well toler-
ated, with efficacy demonstrating comparability with linezolid
[48].
The most frequently reported AEs in the IV studies were
cannula site reactions and elevated ALT levels ranging from 1.9 to
3.8  the upper limit of normal (ULN) in 300e600 mg IV doses.
Nausea (25%) was observed after oral administration only. All
AEs were mild in intensity and resolved by the end of study
[48,49].
On January 2013, FDA has designed omadacycline as a Qualified
Infectious Disease Product (QIDP) for both IV and oral formulations
in the treatment of acute bacterial skin and skin structure infections
and bacterial CAP.88
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13010. Oxazolidones
Tedizolid and radezolid are two new oxazolidinones that are
currently under development; both retain activity against MRSA
strains that are resistant to linezolid [50].
Tedizolid phosphate, is a new oxazolidinone prodrug that is
transformed in the serum into the active drug torezolid. Tedizolid
acts by inhibiting protein synthesis and has broad activity against
Gram (þ) pathogens. The methyl tetrazole D-ring system pick up
(Table 2) additional binding site interactions with the ribosome and
thus confer increased potency, relative to that of linezolid.
Tedizolid is four to eightfold more active in vitro than linezolid
against staphylococci, streptococci and enterococci. Close to 80% of
linezolid resistant strains were inhibited by tedizolid at a concen-
tration of 4 mg/mL [51].
It is highly potent prodrug with good drug properties, solubility
of 130 mg/mL in aqueous solutions of pH  5.0, and 91.7% oral
bioavailability. The elimination half-life (8e11 h) and volume of
distribution for tedizolid were nearly double the values for line-
zolid. It has an intravenous/oral step-down formulation as well as a
6 day oral dosing regimen [52].
Unlike linezolid, it demonstrate 10-fold accumulation in human
macrophages as well intracellular killing of phagocytosed S. aureus,
Listeria monocytogenes and L. pneumophila, which contributes to its
improved pharmacodynamic properties. Lemaire et al. demon-
strated that tedizolid penetrates into macrophages cultured in vitro
and kills intracellular staphylococci better than linezolid, but that
killing is directly related to MIC differential [53].
It shows an improved safety profile that includes decreased
haematological effects at the therapeutic dose [54] and the absence
of a pressor effect in response to tyramine challenge in an animal
model. Unlike linezolid, tedizolid does not inhibit monoamine ox-
idase in vivo, therefore interactions with adrenergic, dopaminergic,
and serotonergic drugs are not to be expected.
In a double-blind Phase 2 clinical study, patients with cSSSIs (a
vast majority had S. aureus and more than 80% had MRSA infection)
were given tedizolid once a day oral doses of 200, 300 or 400mg for
5e7 days. Clinical cure rates in excess of 95% were achieved for
MRSA as well as MSSA infections in all three dosage groups [51].
The side effects reported were nausea, stomach discomfort, diar-
rhea, headache, and dysgeusia.Please cite this article in press as: Liapikou A, et al., New antimicrob
Pharmacology & Therapeutics (2014), http://dx.doi.org/10.1016/j.pupt.201In December 2013, the FDA designated tedizolid as a Qualified
Infectious Disease Product (QIDP), for its potential indication in
ABSSSI.
A Phase 3 comparative trial is currently recruiting patients with
VAP and Gram (þ) bacteremia to compare tedizolide 200 mg IV
once daily for 7 days to linezolid 600 mg every 12 h [55].
11. Discussion
Whereas resistant Gram-negative bacteriawere amajor concern
in previous years, over the last few years a dramatic increase in the
resistance of Gram-positive bacteria has occurred, these have
includedMDR staphylococci, penicillin resistant S. pneumoniae, and
VRE.
Regarding this event we have presented some of the exciting
and noteworthy ongoing developments in the field of antibacterials
against Gram (þ) respiratory pathogens. Our opinion for their
clinical use depends according the site of care:
11.1. CAP treatment
The major problem in the management of CAP is the inability to
determine the aetiological pathogen. Therefore, it is necessary to
carefully consider the various risk factors and epidemiological cir-
cumstances and initiate empirical treatment with antibiotics able
to effectively treat the most likely pathogens causing the infection.
Among the above mentioned new antibiotics approved or not
most appropriate for outpatient treatment will be the two keto-
lides: cethromycin, solithromycin and the quinolone nemonoxacin.
They have oral formulations and are active against the more com-
mon respiratory pathogens. The new tetracycline omadacycline
needs more studies to evaluate its clinical use.
After the hospital admission we have to think Gram () path-
ogens, so we can use ceftaroline and ceftobiprole but not as mon-
otherapy, because there are not active against atypicals.
11.2. HAP treatment
One of the main challenges in the management of HAP is to
overcome the resistance issues. The patients with HAP and espe-
cially with VAP, they will have more often a diagnosis, so we can
select an intravenous antibiotic with a specific spectrum (f.e. anti-
MRSA), as telavancin or tedizolid.
For the Gram (-) microorganisms the dosis of ceftobiprole is not
fixed yet and if the etiologic miccroorganism is P. aeruginosawe can
choose an antipseudomonal b-lactam or a quinolone. We recom-
mend that companies should, in parallel to the efficacy, develop
easy ways to measure blood levels of the new antibiotic especially
in these antimicrobial targeting resistant microorganisms.
Apart from the above new antibiotics we need a strategy that
promotes research, with more trials regarding PK/PD and safety,
into new as well as known but unutilized compounds, allows effi-
cient use, reduces unnecessary overuse, and limits the spread of
antibiotic resistance.
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